Dr. Guru Sonpavde, MD (Clinical Assistant Professor, Baylor College of Medicine) reported about an open label, phase II trial of sunitinib (Sunitinib, marketed as Sutent, and previously known as SU11248 is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and [...]
A post-surgery increase of PSA (usually three increases) is the definition for a prostate cancer recurrence. The best response after these increases is to radiate the prostate bed in hopes for stopping any stray cancer cells that had escaped prior to surgery. Using salvage radiation is the only remaining treatment modality that might allow a [...]
A multi-center Phase III study discussed at the 2009 meeting of the American Urological Association,[1] has demonstrated that the risk for bone fractures in men on androgen deprivation therapy (ADT) can be reduced by using toremifene (Acapodene). Men, fighting advanced prostate cancer, often receive long-term ADT, which along with other side effects will increase their [...]
A multi-center Phase III study was discussed at the 2009 meeting of the American Urological Association.[1] The perliminar results of this study has demonstrated that the risk for incurring bone fractures in men on androgen deprivation therapy (ADT) is reduced when the drug toremifene (Acapodene) is administered. Men, fighting advanced prostate cancer, often receive long-term [...]
Clinical trials are the lifeblood of new drug and treatment development. Trials allow us to learn what developing drugs and treatment are both safe and effective. Many drug developers complain about their inability to attract enough volunteers to reach a sample size that will allow them to draw statistically valid conclusions. Everyday there are trials [...]